Itolizumab

DB16207

biotech investigational

Deskripsi

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25945063
    Menon R, David BG: Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2015 Apr 17;8:215-22. doi: 10.2147/CCID.S47784. eCollection 2015.
  • PMID: 28064543
    Dogra S, Uprety S, Suresh SH: Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther. 2017 Mar;17(3):395-402. doi: 10.1080/14712598.2017.1279601. Epub 2017 Jan 25.
  • PMID: 29033818
    Pai G, Pai AH: Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis. Case Rep Dermatol. 2017 Aug 23;9(2):141-145. doi: 10.1159/000475519. eCollection 2017 May-Aug.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul